

Mouse CXCL4/PF4 Immunoassay

Catalog Number: EA800137

For the quantitative determination of mouse CXCL4/PF4 concentrations in cell culture supernates, serum, and plasma.

For research use only. Not for use in diagnostic procedures.

MANUFACTURED AND DISTRIBUTED BY:

OriGene Technologies,Inc.

9620 Medical Center Drive Suite 200 Rockville, MD 20850,USA

Tel: 1-301-340-3188 Fax: 301-340-9254 Mail: techsupport@origene.com Web: www.origene.com



TABLE OF CONTENTS

SECTION	PAGE	
BACKGROUND		1
PRINCIPLE OF THE ASSAY		1
TECHNICAL HINTS AND LIMITAT	ΓΙΟΝS	2
PRECAUTIONS		2
KIT COMPONENTS& STORAGE C	CONDITIONS	3
OTHER SUPPLIES REQUIRED BU	T NOT SUPPLIED	2
SPECIMEN COLLECTION & STOR	RAGE	2
REAGENTS PREPARATION		4
ASSAY PROCEDURE		6
CALCULATION OF RESULTS		6
PERFORMANCE CHARACTERIST	TCS	8
REFERENCES		10




BACKGROUND

CXCL4/PF4 is a secreted chemokine that is expressed by megakaryocytes and restrains the coagulation cascade. It is released by activated platelets and regulates Thrombin/Thrombomodulin complexes, activated Protein C (APC), Coagulation Factor Xa, and Fibrin. The anticoagulant heparin neutralizes CXCL4 procoagulant effects. Complexes of heparin and CXCL4 trigger antibody formation that causes the pathological syndrome HITT. Immunogenic complexes of CXCL4 with Apolipoprotein H contribute to antiphospholipid syndrome (APS). CXCL4 interferes with the proliferative and angiogenic functions of FGF-2 and VEGF. However, it can also exert proinflammatory and pro-atherogenic effects on monocytes, macrophages, and endothelial cells. CXCL4 may signal through CXCR3B in humans.

PRINCIPLE OF THE ASSAY

This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for CXCL4/PF4 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any CXCL4/PF4 present is captured by the coated antibody after incubation. Following extensive washing, a biotin-conjugate antibody specific for CXCL4/PF4 is added to detect the captured CXCL4/PF4 protein in sample. For signal development, horseradish peroxidase (HRP)-conjugated Streptavidin is added, followed by tetramethyl-benzidine (TMB) reagent. Following a wash to remove any unbound combination, and enzyme conjugate is added to the wells. Solution containing sulfuric acid is used to stop color development and the color intensity which is proportional to the quantity of bound protein is measurable at 450nm.

Schematic diagram:





TECHNICAL HINTS AND LIMITATIONS

- 1. This ELISA should not be used beyond the expiration data on the kit label.
- 2. To avoid cross-contamination, use a fresh reagent reservoir and pipette tips for each step.
- 3. To ensure accurate results, some details, such as technique, plasticware and water sources should be emphasized.
- 4. A thorough and consistent wash technique is essential for proper assay performance.
- 5. A standard curve should be generated for each set of samples assayed.
- 6. It is recommended that all standards and samples be assayed in duplicate.
- 7. Avoid microbial contamination of reagents and buffers. Buffers containing protein should be made under aseptic conditions and be prepared fresh daily.
- 8. In order to ensure the accuracy of the results, the standard curve should be made every time.

PRECAUTIONS

The Stop Solution suggested for use with this kit is an acid solution. Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after handling.



KIT COMPONENTS& STORAGE CONDITIONS

PART	SIZE	STORAGE OF OPENED/ RECONSTITUTED MATERIAL
Microwell Plate - antibody coated 96-well Microplate (8 wells ×12 strips)	1 plate	Return unused wells to the foil pouch containing the desiccant pack. Reseal along entire edge of the zip-seal. May be stored for up to 1 month at $2-8^{\circ}C^{**}$
Standard -lyophilized,2000 pg/vial upon reconstitution	2 vials	Aliquot and Store at -20°C** for six months
Concentrated Biotin-Conjugated antibody(100X) - 120 ul/vial	1 vial	Store at 2-8°C **for six months
Concentrated Streptavidin-HRP solution(100X) - 120 ul/vial	1 vial	Store at 2-8°C** for six months
Standard /Sample Diluent - 16 ml/vial	1 bottle	Store at 2-8°C** for six months
Biotin-Conjugate antibody Diluent - 16 ml/vial	1 bottle	Store at 2-8°C** for six months
Streptavidin-HRP Diluent - 16 ml/vial	1 bottle	Store at 2-8°C** for six months
Wash Buffer Concentrate (20x) - 30 ml/vial	1 bottle	Store at 2-8°C** for six months
Substrate Solution - 12 ml/vial	1 bottle	Store at 2-8°C** for six months
Stop Solution - 12 ml/vial	1 bottle	Store at 2-8°C** for six months
Plate Cover Seals	4 pieces	

^{**}Provided this is within the expiration date of the kit.



OTHER SUPPLIES REQUIRED BUT NOT SUPPLIED

- 1. Microplate reader capable of measuring absorbance at 450 nm.
- 2. Pipettes and pipette tips.
- 3. Deionized or distilled water.
- 4. Squirt bottle, manifold dispenser, or automated microplate washer.
- 5. 500 mL graduated cylinder.

SPECIMEN COLLECTION & STORAGE

Cell Culture Supernates - Centrifuge cell culture media at $1000 \times g$ to remove debris. Assay immediately or aliquot and store samples at \leq -20 °C. Avoid repeated freezethaw cycles.

Serum - Use a serum separator tube (SST) and allow samples to clot for 2 hours at room temperature or overnight at 2-8°C. Centrifuge approximately for 15 minutes at $1000 \times g$. Assay immediately or aliquot and store samples at \le -20 °C. Avoid repeated freeze-thaw cycles.

Plasma - Collect plasma using EDTA, heparin, or citrate as an anticoagulant. Centrifuge for 15 minutes at $1000 \times g$ within 30 minutes of collection. Assay immediately or aliquot and store samples at \leq -20 °C. Avoid repeated freeze-thaw cycles.


Note: The normal mouse serum or plasma samples are suggested to make a 1:2 dilution.

REAGENTS PREPARATION

- **1. Temperature returning** Bring all kit components and specimen to room temperature (20-25°C) before use.
- 2. Wash Buffer Dilute 30mL of Wash Buffer Concentrate with 570mL of deionized or distilled water to prepare 600mL of Wash Buffer. If crystals have formed in the concentrate Wash Buffer, warm to room temperature and mix gently until the crystals have completely dissolved.
- 3. **Standard/Specimen** Reconstitute the Standard with 1.0mL of Standard/Sample Diluent. This reconstitution produces a stock solution of 2000 pg/mL. Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making dilutions. Pipette 500μL of Standard/ Sample Diluent into 1000pg/ml tube and the remaining tubes. Use the stock solution of 2000pg/mL to produce a 2-fold



dilution series (below). Mix each tube thoroughly and change pipette tips between each transfer. The 2000 pg/mL standard serves as the high standard. The Standard/ Sample Diluent serves as the zero standard (0 pg/mL).



Preparation of CACL4/PF4 Standard unduons

- *If you do not run out of re-melting standard, store it at -20°C. Diluted standard shall not be reused.
- **4. Working solution of Biotin-Conjugate anti-mouse CXCL4/PF4 antibody:** Make a 1:100 dilution of the concentrated Biotin-Conjugate solution with the Biotin-Conjugate antibody Diluent in a clean plastic tube.
 - *The working solution should be used within one day after dilution.
- **5. Working solution of Streptavidin-HRP**: Make a 1:100 dilution of the concentrated Streptavidin-HRP solution with the Streptavidin-HRP Diluent in a clean plastic tube.
 - *The working solution should be used within one day after dilution.

ASSAY PROCEDURE



Prepare all reagents and standards as directed. Wash the plate 3 times before assay.

Д

Add 100µl standard or samples to each well, incubate 90 minutes, 37°C.

 \prod Aspirate and wash 4 times

Add 100µl working solution of Biotin-Conjugate anti-mouse CXCL4/PF4 antibody to each well, incubate 60 minutes,37°C.

 \square Aspirate and wash 4 times

Add 100µl working solution of Streptavidin-HRP to each well, incubate 30 minutes,37°C.

Aspirate and wash 5 times

Add 100µl Substrate solution to each well, incubate 15 minutes,37°C.Protect from light.

 \int

Add 50µl Stop solution to each well. Read at 450nm within 5 minutes.

CALCULATION OF RESULTS


- 1. The standard curve is used to determine the amount of specimens.
- 2. First, average the duplicate readings for each standard, control, and sample. All O.D. values are subtracted by the mean value of blank control before result interpretation.
- 3. Construct a standard curve by reducing the data using computer software capable of generating a four parameter logistic (4-PL) curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph.
- 4. The data may be linearized by plotting the log of the CXCL4/PF4 concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.
- 5. This standard curve is provided for demonstration only. A standard curve should be generated for each set of samples assayed.

Typical data using the CXCL4/PF4 ELISA

Standard(pg/	OD.	OD.	Average	Corrected
ml)	OD.	OD.	Average	Corrected



0	0.054	0.052	0.053	
31.25	0.086	0.092	0.089	0.036
62.5	0.167	0.176	0.171	0.118
125	0.293	0.302	0.297	0.244
250	0.521	0.545	0.533	0.480
500	0.883	0.857	0.870	0.817
1000	1.567	1.546	1.556	1.503
2000	2.631	2.662	2.646	2.593



Representative standard curve for CXCL4/PF4 ELISA.



Performance Characteristics

SENSITIVITY: The minimum detectable dose was 15pg/mL.

SPECIFICITY: This assay recognizes both natural and recombinant mouse CXCL4/ PF4. The factors listed below were prepared at 100ng/ml in Standard /sample Diluent and assayed for cross-reactivity and no significant cross-reactivity or interference was observed.

Factors assayed for cross-reactivity

Recombinant mouse	Recombinant rat	Recombinant human
CXCL10/IP-10/CRG-2		LRP-1
IL-3		CXCL8/IL-8
Thrombomodulin		CXCL4/PF4
VEGF120		
VEGF164		

REPEATABILITY: The coefficient of variation of both intra-assay and inter-assay were less than 10%.

RECOVERY: The recovery of CXCL4/PF4 spiked to three different levels in four samples throughout the range of the assay in various matrices was evaluated.

Recovery of CXCL4/PF4 in two matrices

Sample Type	Average % of Expected Range (%)	Range (%)
Citrate plasma	86	79-97
Cell culture supernatants	90	81-101



LINEARITY: To assess the linearity of the assay, three samples were spiked with high concentrations of CXCL4/PF4 in various matrices and diluted with the appropriate Sample Diluent to produce samples with values within the dynamic range of the assay. (The plasma samples were initially diluted 1:1)

Dilution ratio	Recovery (%)	Citrate plasma	Cell culture supernatants
1:2	Average% of Expected	95	103
1.2	Range (%)	84-103	96-114
1:4	Average% of Expected	92	105
	Range (%)	84-101	96-113
1:8	Average% of Expected	93	106
	Range (%)	83-113	98-115
1:16	Average% of Expected	96	104
	Range (%)	88-108	97-112



REFERENCES

- 1. Poncz, M. et al. (1987) Blood 69:219.
- 2. Kowalska, M.A. et al. (2010) Thromb. Res. 125:292.
- 3. Slungaard, A. (2005) Int. J. Biochem. Cell Biol. 37:1162.
- 4. Zhang, X. et al. (1994) Biochemistry 33:8361.
- 5. Briquet-Laugier, V. et al. (2004) J. Thromb. Haemost. 2:2231.
- 6. El Golli, N. et al. (2005) J. Biol. Chem. 280:30329.
- 7. Petersen, F. et al. (1998) J. Immunol. 161:4347.
- 8. Petersen, F. et al. (1999) J. Biol. Chem. 274:12376.
- 9. Dudek, A.Z. et al. (2003) Blood 101:4687.
- 10. Slungaard, A. et al. (2003) Blood 102:146.
- 11. Kowalska, M.A. et al. (2007) Blood 110:1903.
- 12. Preston, R.J.S. et al. (2009) J. Biol. Chem. 284:5869.
- 13. Fiore, M.M. and I.J. Mackie (2009) Biochem. Biophys. Res. Commun. 379:1072.
- 14. Amelot, A.A. et al. (2007) J. Biol. Chem. 282:710.
- 15. Eslin, D.E. et al. (2004) Blood 104:3173.
- 16. Warkentin, T.E. et al. (2009) Blood 113:4963.
- 17. Sikara, M.P. et al. (2010) Blood 115:713.
- 18. Lambert, M.P. et al. (2007) Blood 110:1153.
- 19. Lambert, M.P. et al. (2009) Blood 114:2290.
- 20. Nesmelova, I.V. et al. (2005) J. Biol. Chem. 280:4948.